Loading...
Should patients with high-risk localised or locally advanced prostate cancer receive abiraterone acetate in addition to androgen deprivation therapy? update on a planned analysis of the STAMPEDE Trial
Attard, G. Brown, L. C. Clarke, Noel W Parmar, M. K. B James, N. D.
Attard, G.
Brown, L. C.
Clarke, Noel W
Parmar, M. K. B
James, N. D.
Citations
Altmetric:
Abstract
None
Description
Date
2021
Publisher
Collections
Keywords
Type
Other
Citation
Attard G, Brown LC, Clarke NW, Parmar MKB, James ND. Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. European Urology. 2021 Jul.